A meta-analysis of mortality in @entity454 XXXX receiving @entity737 ( @entity737 ).

@entity1 @entity1479 @entity712 @entity740 @entity737 @entity1349 @entity454
Data on the effectiveness of implantable @entity737 ( @entity737 ) with respect to reducing mortality in @entity1 with @entity740 ( @entity740 ) and @entity454 ( @entity454 ) are lacking. The purpose of this meta-analysis was to compare the mortality of @entity1 with @entity454 who have received and not received an @entity1479 . A search was conducted on January 31, 2013 of Medline, Cochrane, EMBASE, and Google Scholar. Studies were selected for inclusion based on the following criteria. 1) Randomized controlled trial. 2) @entity454 @entity1 with @entity712 . 3) Device therapy ( @entity1479 , CRT-defibrillator [CRT-D]) used to treat @entity712 . 4) Primary outcome is survival analysis. 5) Retrospective study if survival analysis was performed. The primary outcome was @entity1349 ( @entity1349 ), and the secondary outcome was 2-year survival. Odds ratios (ORs) with 95% confidence intervals (CI) were calculated, and a   2-based test of homogeneity was performed. Three studies were included in the analysis. The combined OR for @entity1349 was 2.245 (95% CI 1.871 to 2.685, P<0.001), indicating that @entity1 with an @entity1479 had a significantly higher @entity1349 than those without an @entity1479 . The combined OR for 2-year survival was 2.312 (95% CI 1.921 to 2.784, P<0.001), indicating that @entity1 with an @entity1479 had a significantly higher 2-year survival rate than those without an @entity1479 . The use of @entity1479 in @entity1 with @entity454 is associated with an increase in the @entity1349 and the 2-year survival rate.
